ATYR PHARMA INC (ATYR)
US0021202025 - Common Stock
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors...
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
Independent data and safety monitoring board (DSMB) review includes all 268 patients who have been enrolled in the study and recommends continuation of study without any modifications.
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
ATYR0101 interacts with LTBP-1 to induce myofibroblast apoptosis through a novel anti-fibrotic mechanism to reduce fibrosis and fibrotic markers in models of lung and kidney fibrosis.
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis ...
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis...
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update ...
aTyr Pharma to Present at Upcoming Investor Conferences
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting...
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal ...
aTyr Pharma to Participate in September Investor Conferences
aTyr Pharma to Participate in September Investor Conferences
aTyr Pharma to Participate in September Investor Conferences...
ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2024
ATYR stock results show that aTyr Pharma beat analyst estimates for earnings per share the second quarter of 2024.
ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips aTyr Pharma (NASDAQ:ATYR) just reported results for the second quarter of 2024....
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update ...
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
aTyr Pharma Announces Research Study with Stanford Medicine
Study to explore role of the Company’s anti-NRP2 antibodies in glioblastoma multiforme (GBM), the most common type of primary brain cancer.
Thursday 7/25 Insider Buying Report: UBFO, ATYR
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis...
ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2023
ATYR stock results show that aTyr Pharma beat analyst estimates for earnings per share the second quarter of 2023.
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
Ticker symbol change to take effect on Wednesday, June 5, 2024
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR” ...